The global fecal calprotectin test market is projected to reach US$ 276.6 million by 2030, from US$ 122.8 million in 2023, at a CAGR of 12.3% during the forecast period 2023-2030.
The growth of the fecal calprotectin test market is driven by the increasing prevalence of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. IBD is a chronic condition that causes inflammation of the digestive tract. Fecal calprotectin is a protein that is released by white blood cells in the intestines. It is elevated in people with IBD, making it a useful biomarker for diagnosing and monitoring the disease.
The increasing awareness about IBD and its symptoms is also driving the growth of the fecal calprotectin test market. People are more likely to seek medical attention if they are aware of the symptoms of IBD, which can lead to early diagnosis and treatment.
Fecal Calprotectin Test Market Trends
Fecal Calprotectin Test Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients